{"id":"r-fsh-plus-hp-hmg","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain/bloating"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:19:59.844988","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"r-FSH directly stimulates follicle-stimulating hormone receptors on granulosa cells to promote follicle growth and estrogen production. HP-hMG provides additional luteinizing hormone (LH) activity to support androgen production in theca cells and final oocyte maturation. Together, they coordinate the hormonal cascade necessary for controlled ovarian hyperstimulation in fertility treatment.","oneSentence":"A combination of recombinant follicle-stimulating hormone (r-FSH) and highly purified human menopausal gonadotropin (HP-hMG) that stimulates ovarian follicle development and hormone production for assisted reproductive technology.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:40.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF)"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT01623570","phase":"NA","title":"Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP","status":"COMPLETED","sponsor":"Centro Riproduzione e Andrologia","startDate":"2011-03","conditions":"Hypogonadotropic Hypogonadism","enrollment":40},{"nctId":"NCT01330771","phase":"","title":"Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2006-10","conditions":"Sterility","enrollment":51},{"nctId":"NCT00829075","phase":"PHASE4","title":"Impact of Three Different Gonadotrophin Regimes on Egg Donation Program","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2005-01","conditions":"Ovarian Stimulation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2019 Oct","pmid":"30973022","title":"The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.","journal":"Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology"},{"date":"2018 Jul 18","pmid":"30021630","title":"Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.","journal":"Reproductive biology and endocrinology : RB&E"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"r-FSH plus HP-hMG","genericName":"r-FSH plus HP-hMG","companyName":"Instituto Valenciano de Infertilidad, IVI VALENCIA","companyId":"instituto-valenciano-de-infertilidad-ivi-valencia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination of recombinant follicle-stimulating hormone (r-FSH) and highly purified human menopausal gonadotropin (HP-hMG) that stimulates ovarian follicle development and hormone production for assisted reproductive technology. Used for Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}